Janssen Pharmaceutical leader says collaborations are critical in fight against HIV

Dr. Wim Parys says beating HIV will only be possible through collaborations.
Dr. Wim Parys says beating HIV will only be possible through collaborations. | File photo

HIV does not have one solution, which makes scientific collaborations vital for developing treatments and vaccines.

Dr. Wim Parys, vice president and head of R&D for the Janssen Pharmaceutical Companies of Johnson & Johnson, recently published an article calling for more collaborations. He says beating HIV is only possible with these important collaborations.

One of the populations most affected by HIV infections is women living in sub-Saharan Africa. Approximately 59 percent of people with HIV infections are women living in this area, and 1,000 more young women contract HIV infections every day.

Without collaborations, scientists will not be able to accumulate their knowledge to create, review and accept a wide range of methods, mindsets and approaches that will help patients around the world. Parys said it is important to remain open minded about the range of options researchers have for their innovations.

These collaborations should also strive for strategic partnerships between industries, public-private partnerships, nonprofit organizations, or a variety of combinations of these agencies for change. 

An example is Janssen Sciences Ireland UC, which has teamed with the International Partnership for Microbicides to send its antiretroviral treatments to people around the world.

Organizations in this Story

Johnson & Johnson

Want to get notified whenever we write about Johnson & Johnson ?
Next time we write about Johnson & Johnson, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.